1. APEX
Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous enoxaparin for 10 days (n = 3,754).
(p = 0.054)
Results
Asymptomatic proximal deep-vein thrombosis or symptomatic venous thromboembolism: 6.9% of the betrixaban group versus 8.5% of the enoxaparin group (p = 0.054)
Major bleeding: 0.7% versus 0.6% (p = 0.55), respectively, for betrixaban versus enoxaparin
8.5 %
6.9
Conclusions
Among patients hospitalized with an acute medical illness, extended-duration betrixaban was not superior to short-duration enoxaparin in preventing thrombotic complications
Bleeding was similar between the groups
Betrixaban
Enoxaparin
Cohen AT, et al. N Engl J Med 2016;375:534-44